Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia.

ABSTRACT: Next-generation cellular immunotherapies seek to improve the safety and efficacy of approved CD19 chimeric antigen receptor (CAR) T-cell products or apply their principles across a growing list of targets and diseases. Supported by promising early clinical experiences, CAR modified natural killer (CAR-NK) cell therapies represent a complementary and potentially off-the-shelf, allogeneic solution. While acute myeloid leukemia (AML) represents an intuitive disease in which to investigate CAR based immunotherapies, key biological differences to B-cell malignancies have complicated progress to date. As CAR-T cell trials treating AML are growing in number, several CAR-NK cell approaches are also in development. In this review we explore why CAR-NK cell therapies may be particularly suited to th

SUBMITTER: Gurney M 

PROVIDER: S-EPMC8036691 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature